Diabetes Mellitus, Type 2 Clinical Trials

Don’t let diabetes lead to heart problems. Lend a hand to help us research a potential medication that might prevent them. The PROMINENT Study is researching a potential new medication (study drug) for people with type 2 diabetes and elevated triglycerides (a type of fat in the blood) to see ...

Do you or someone you know suffer from Diabetes? Are you taking Metformin or are Naïve to Diabetes medications? If so, you may be eligible to participate in a research study for an investigational Diabetes medication If you qualify you will receive all study-related examinations, lab work and study medications ...

A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control ...

Northern California Research is conducting a study for diabetic peripheral neuropathy (DPN). DPN is a type of nerve damage that can occur if you have diabetes. This study is for men and women who are experiencing painful diabetic peripheral neuropathy in both lower extremities (legs). The specific events that result ...

Diabetics are at a higher risk for chronic kidney disease since high blood sugar levels caused by diabetes damage blood vessels in the kidneys. If the blood sugar level remains high over many years, this damage gradually reduces the function of the kidneys. Your kidneys filter wastes and excess fluids ...

Researchers at the University of Kentucky are inviting you to participate in a study investigating ways to prevent diabetes or obesity. This study will involve a one-time blood draw.

The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with T2DM and to compare outcomes against placebo, on a background of standard of care.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.

The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)

The aim of the trial is to compare the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs.